| Survival: | 4.8 months |
| Toxicity Grade: | 5 |
| Treatments: | Chemotherapy |
| Drugs: | Adriamycin |
| Country: | United States |
| City/State/Province: | La Jolla, California |
| Hospital: | Scripps Clinic |
| Journal: | Link |
| Date: | 11/2001 |
| Description: |
| Patients: This Phase II study involved 10 patients with malignant mesothelioma. Treatment: The treatment consisted of the chemotherapy drug doxorubicin (adriamycin) (high-dose) with the drugs dexrazoxane (for cardio-protection), and GM-CSF (to lessen bone marrow toxicity). Toxicity: One patient died of sepsis. In addition, grade 3-4 toxicities included hematologic, infection, esophagitis/dysphagia, and cardiac function. This study was terminated early due to excessive toxicity. Results: No patient responded to treatment and the median overall survival was 4.8 months. Correspondence: Michael P. Kosty, MD |